REVIEW PAPER
Lyme arthritis – symptoms and treatment
Online publication date: 2013-03-05
Reumatologia 2013;51(1):51-55
KEYWORDS
ABSTRACT
Lyme borreliosis is a chronic, multisystemic inflammatory disease caused by the tick-borne spirochete Borrelia. The musculoskeletal system is often affected during the disease and Borrelia burgdorferi is a pathogen. Rheumatological symptoms often vary, with a wide spectrum of often non-characteristic features. They include mild, transient pain in the musculoskeletal system, acute arthritis with articular exudate and chronic destructive arthritis, which, however, is not very common (about 10%). In general, diagnosis of Lyme arthritis is difficult and is based on clinical symptoms of arthritis in combination with clinical history and immunoserological tests. In most patients prognosis is good due to high effectiveness of the antibiotic therapy.
REFERENCES (37)
1.
Sigal LH. Lyme disease: a review of aspects of its immunology and immunopathogenesis. Ann Rev Immunol 1997; 15: 63-92.
2.
Hytönen J, Hartiala P, Oksi J, et al. Borreliosis: recent research, diagnosis, and management. Scand J Rheumatol 2008; 37: 161-172.
4.
Flisiak R, Pancewicz S. Diagnostyka i leczenie Boreliozy z Lyme – rekomendacje Polskiego Towarzystwa Epidemiologicznego i Lekarzy Chorób Zakaźnych. Przegl Epidemiol 2008; 62: 193-199.
5.
Grygorczuk S, Pancewicz S, Zajkowska J i wsp. Postać stawowa boreliozy z Lyme. Pol Merkur Lek 2008; 24: 542-544.
6.
Orloski KA, Hayes EB, Campbell GL, et al. Surveillance for Lyme disease – United States, 1992–1998. MMWRCDC Surveill Summ 2000; 49: 1-11.
7.
Balmelli T, Piffaretti JC. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. Res Microbiol 1995; 146: 329-340.
8.
Steere AC, Schoen R, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987; 107: 725-731.
10.
Centers for Disease Control and Prevention (CDC). Lyme disease – United States, 2001–2002. MMWR Morb Mortal Wkly Rep 2004; 53: 365-369.
11.
Cimmino MA. Relative frequency of Lyme borreliosis and of its clinical manifestations in Europe. European Community Concerted Action on Risk Assessment in Lyme Borreliosis. Infection 1998; 26: 298-300.
12.
Huppertz HI, Böhme M, Standaert SM, et al. Incidence of Lyme borreliosis in the Würzburg region of Germany. Eur J Clin Microbiol Infect Dis 1999; 18: 697-703.
13.
Pancewicz SA, Rutkowski R, Rutkowski K i wsp. Zaburzenia immunologiczne w zapaleniu stawów w boreliozie z Lyme. Pol Merkur Lek 2007; 23: 141-144.
14.
Steere AC, Drouin EE, Glickstein LJ. Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis. Clin Infect Dis 2011; 52 Suppl 3: 259-265.
15.
Trollmo C, Meyer AL, Steere AC, et al. Molecular mimicry in Lyme arthritis demonstrated at the single cell level: LFA-1 alpha L is a partial agonist for outer surface protein A-reactive T cells. J Immunol 2001; 166: 5286-5291.
16.
Szechiński J. Borelioza. W: Reumatologia kliniczna. Zimmermann--Górska I (red.). Wydawnictwo Lekarskie PZWL, Warszawa 2008; 799-804.
17.
Kondrusik M, Swierzbińska R, Zajkowska JM i wsp. Wpływ antybiotykoterapii na stężenie cytokin prozapalnych: interleukin – IL-1, .
18.
oraz czynnika martwicy nowotworu – TNF-αlfa w surowicy chorych z boreliozą z Lyme. Wiad Lek 2002; 55: 276-281.
19.
Jabłońska E, Marcinczyk M, Talarek L i wsp. IL-15 in the culture supernatants of PMN and PBMC and the serum of patients with Lyme disease. Rocz Akad Med Bialystok 2003; 48: 78-81.
20.
Łuczaj W, Moniuszko A, Rusak M, et al. Lipid peroxidation products as potential bioindicators of Lyme arthritis. Eur J Clin Microbiol Infect Dis 2011; 30: 415-422.
21.
Steere AC, Hardin JA, Malawista SE. Erythema chronicum migrans and Lyme arthritis: cryoimmunoglobulins and clinical activity of skin and joints. Science 1977; 196: 1121-1122.
22.
Steere AC, Angelis SM. Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis. Arthritis Rheum 2006; 54: 3079-3086.
23.
Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med 1990; 323: 219-223. .
24.
Steere AC, Klitz W, Drouin EE, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide. J Exp Med 2006; 203: 961-971.
27.
Flisiak R. Boreliozy. W: Choroby przenoszone przez kleszcze. Prokopowicz D (red.) Wydawnictwo Fundacji PJB Büchnera. Warszawa 1995; 119-143.
28.
Flisiak R, Prokopowicz D. Clinical picture of Lyme boreliosis. Wiad Parazytol 1999; 45: 143-149.
29.
Rydz-Stryszowska I, Batko B, Krawiec P i wsp. Boreliozowe zapalenie stawów. Przegl Lek 2007; 64: 111-114.
30.
Sigal LH. Lyme disease: a review of aspects of its immunology and immunopathogenesis. Annu Rev Immunol 1997; 15: 63-92.
31.
Steere, AC Levin RE, Molloy PJ, et al. Treatment of Lyme arthritis. Arthritis Rheum 1994; 37: 878-888.
32.
Nocton JJ, Dressler F, Rutledge BJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N Engl J Med 1994; 330: 229-234.
33.
Centers for Disease Control and Prevention (CDC). Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44: 590-591.
34.
Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. CID, 2006; 43: 1089-1133.
36.
Steere A. Duration of Antibiotic therapy in Lyme Disease, Ann Int Med 2003; 9: 761-762.
37.
Brorson O, Brorson SH. An in vitro study of the susceptibility of mobile and cystic forms of Borrelia burgdorferi to hydroxychloroquine. Int Microbiol 2002; 5: 25-31.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
